Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2017 08:30 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017

NEWTOWN, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to...
December 06, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting

NEWTOWN, Pa. and SAN JOSE, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering...
December 05, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting

--35% Complete Remission (CR) Rate for Combination in 1st-line Higher-risk MDS Patients-- --Updated Median Duration of Complete Response of 8 Months in All Responding Patients-- NEWTOWN, Pa., Dec....
November 14, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results

NEWTOWN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to...
November 04, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting

--Rigosertib plus Azacitidine Combination Phase 2 Trial Results Featured-- NEWTOWN, Pa., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage...
October 13, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum

NEWTOWN, Pa., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
October 10, 2016 08:52 ET | Source: Onconova Therapeutics

Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City

NEWTOWN, Pa., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
September 26, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination

NEWTOWN, Pa., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
September 07, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences

NEWTOWN, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
August 15, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

NEWTOWN, Pa., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...